01
Cash & equivalents increased 25.5%
Cash & equivalents changed +25.5% from the comparable as-filed period.
$16.5M→$20.7MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTHERON THERAPEUTICS, INC. /DE/'s latest supported as-filed period reports interest income of -$552,000. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +25.5% from the comparable as-filed period.
Gross profit changed -4.6% from the comparable as-filed period.
Inventory changed +24.1% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
HRTX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-352403SEC ↗4Aug 10, 2026Period Aug 6, 20260001193125-26-341528SEC ↗10-QAug 10, 2026Period Jun 30, 20260001193125-26-341301SEC ↗8-KAug 10, 2026Period Aug 10, 20260001193125-26-341300SEC ↗4Aug 3, 2026Period Jul 31, 20260001193125-26-329848SEC ↗4Aug 3, 2026Period Jul 30, 20260001193125-26-329804SEC ↗4Aug 3, 2026Period Jul 30, 20260001193125-26-329720SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 6, 2026Filed Aug 10, 2026 | Hensley Mark EarlChief Operating Officer | Option ExerciseDirect | 31,250 | — | — | Form 4 ↗ |
| Aug 6, 2026Filed Aug 10, 2026 | Hensley Mark EarlChief Operating Officer | Tax WithholdingDirect | 8,888 | $1 | $4,444 | Form 4 ↗ |
| Aug 6, 2026Filed Aug 10, 2026 | Hensley Mark EarlChief Operating Officer | Option ExerciseDirect | 31,250 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Net income changed -130.5% from the comparable as-filed period.
Operating income changed -24.9% from the comparable as-filed period.
Research & development changed -7.9% from the comparable as-filed period.
Stock-based compensation changed +13.6% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-329694